Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (Q84574792)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 September 2009

Language	Label	Description	Also known as
English	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML	scientific article published on 21 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Stephen Devereux

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Antonio Pagliuca

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Z Y Lim

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

W Ingram

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

R Brand

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Ho

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

M Kenyon

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Marsh

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

G J Mufti

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

21 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

45

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

633-639

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19767782%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

https://scigraph.springernature.com/pub.10.1038/bmt.2009.236

0 references

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

A risk score for mortality after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.236

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84574792&oldid=1530843286"